The, G K H, Prins, J, Bleijenberg, G et al. · The Netherlands journal of medicine · 2003
Researchers tested whether a medication called granisetron, which affects a brain chemical involved in nausea and other functions, might help ME/CFS patients feel less fatigued. Five women with ME/CFS took the medication for one month and reported significant improvements in how tired they felt and how much they could do. However, this was a very small study without a comparison group, so much more research is needed to confirm these results.
This study proposes a novel mechanistic target—5-HT3 receptors—for ME/CFS treatment, potentially opening a new therapeutic avenue if confirmed in larger trials. Understanding which neurobiological pathways drive ME/CFS symptoms is crucial for developing effective interventions, and pilot studies help identify promising candidates for rigorous testing.
This pilot study does not establish that granisetron is effective for ME/CFS, as it lacks a placebo control group and involves only five female patients. The improvements observed could be due to placebo effect, natural fluctuation in symptoms, or regression to the mean. Results cannot be generalized to male patients or broader CFS populations without larger, controlled studies.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →